Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.

Also called NCT07389941

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07389941
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07389941. Randomized; single masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2029-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
Acronym
SPICE-AF
Condition
Atrial Fibrillation (AF)
Intervention (Drug)
Semaglutide (SEMA)
Lead sponsor
University of Luebeck (class: other)

Record details

Record id
cardio:ct-nct07389941
Content hash
9a46e3e643eb2e471c8598880dd3d5d7b2e2a9615baf378deb9603061a6dad9e